Atrium Health Foundation has been awarded generous funding from Global Blood Therapeutics through the company’s 2020 Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program. Funding will support Atrium Health’s Levine Children’s Cancer and Blood Disorders Clinic in its work to expand access to care for pediatric sickle cell patients by educating and empowering their primary care providers to deliver sickle cell care and reinforce education.
“Individuals living with sickle cell disease (SCD) face significant challenges every day, including accessing quality healthcare in their communities. These challenges are greater than ever given the impact of COVID-19 and the healthcare disparities the pandemic has brought harshly to light,” said Jung E. Choi, Chief Business and Strategy Officer, and head of patient advocacy and government affairs at GBT.
Over the last few decades, Atrium Health has stood at the forefront of new innovations and therapies to bring drastic improvement to sickle cell disease patients’ quality of life. Beginning as early as childhood, Levine Children’s Hospital’s pediatric sickle cell program ensures that patients receive cutting edge treatments and guides them in their transition of care as they enter adulthood to begin treatment at Atrium Health’s Levine Cancer Institute. Atrium Health is also participating and engaging in clinical research and clinical trials in the treatment of sickle cell disease.
With many thanks to Global Blood Therapeutics, Atrium Health will continue advancing its commitment to improve health equity by reducing disparities in care.